Research programme: GPCR targeting therapeutics - Heptares

Drug Profile

Research programme: GPCR targeting therapeutics - Heptares

Latest Information Update: 09 Feb 2017

Price : $50

At a glance

  • Originator Heptares Therapeutics
  • Developer Heptares Therapeutics; National Heart and Lung Institute; University of Cambridge
  • Class Anti-inflammatories; Antiasthmatics; Small molecules
  • Mechanism of Action G protein-coupled receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Research Asthma; Cardiovascular disorders; Immunological disorders; Inflammatory bowel diseases

Most Recent Events

  • 31 Jan 2017 Early research in Cardiovascular disorders in United Kingdom (unspecified route)
  • 02 Feb 2016 Early research in Asthma in USA, United Kingdom (unspecified route)
  • 02 Feb 2016 Early research in Immunological disorders in United Kingdom, USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top